The paper 'Strategic Analysis of AstraZeneca Pharmaceuticals US" is a good example of a business case study. One of the toughest challenges facing the world today is improving health. Being a worldwide biopharmaceutical company, AstraZeneca plays a crucial role in medicines that result in a real difference in health. The company acknowledges that it cannot work in isolation to deliver medicines that are of value to the people. This implies that it works closely with stakeholders to understand the public needs. By combining forces, the company is able to develop measures of how to improve healthcare.
It has a strong belief that we are all connected by health. Strategic Analysis of AstraZeneca Pharmaceuticals US Mission Statement AstraZeneca US is a company that is committed to achieving a mission of improving human health globally. The community of AstraZeneca is to: Discovering, developing, and delivering innovative, effective medicines and other healthcare solutions aimed at helping to enrich the lives of patients, and society. Putting the health of patients as the first priority by providing educational programs, resources, and materials meant to help empower and inform them of the importance of quality healthcare. Encouraging a challenging and rewarding work environment that inspires and motivates the company’ s employees Introduction AstraZeneca is a company committed to achieving success, and the culture of the licensing of products and technologies is a strategic priority that has been acknowledged. The Company in Detail AstraZeneca was created on 6 April 1999.
It resulted as a merger of Sweden’ s Astra and the UK’ s Zeneca group. Astra was originally formed in 1913 and had its head offices in Sodertalje, Sweden. It majored in pharmaceutical developments conducting research and marketing in four distinct research categories including gastrointestinal, cardiovascular, as well as respiratory and pain control, including medical devices. Zeneca was created in mid-1993 when Imperial Chemical Industries split three of its businesses.
Zeneca had been a leading global bioscience group dealing with research, production and marketing of pharmaceutical products.
Agarwal, S., Desai, S., Holcomb, M. & Oberoi, A. (2001). Unlocking The Value Of Big Pharma’,The Mckinsey Quarterly. Washington: Greenwood Press Publishers
Astrazeneca (2001a). Astrazeneca Approach to E-Business. New York: Penguin
Astrazeneca, (2001b). Astrazeneca Approach to E-Business’, Presentation to Analysts. New York, NY: Penguin
Blumberg, D. & Perrone, F. (2001). How Much Are Marketing and Sales Capabilities Reallyworth? A European Study On How The Capabilities Drive Performance. Washington: Sage Publications
Brownlee, J., & Shannon C. (2004). Doctors Without Borders: Why You Can’t Trust Medical Journals Anymore. California: Sage Publications
Carroll S., Bernard J. & Rubin, Robert T. (2003). Correspondence: Editorial Polices On Financial Disclosure. Nature Neuroscience. New York: Prentice Hall
Drugs and Pharmaceuticals, (2004). International Pharmaceutical Industry-A Snapshot. New York: Prentice Hall
Pharmaceutical Research and Manufacturers of America (PHARMA) (2001). Pharmaceutical Industry Profile 2001. Washington: Sage Publications
Pierre A. (2001). “Do Pharmaceutical Sales Respond To Scientific Evidence? Evidence from Anti-Ulcer Drugs”, Columbia: Greenwood Press
Prathap, G., Micheal, R., & Vikalpa, S. (2005). “International Marketing Strategies in U.S” New York: Create Space Publishers
Smarta, G., & Raja B. (1994). Strategic Pharmaceutical Marketing. New Delhi: Greenwood Press
Tufts Centre for the Study of Drug Development (2001). ‘Tufts Center for the Study of Drug Development Pegs Cost Of a New Prescription Medicine at $802 Million’, California: Sage Publications
Venugopal, P.V. (1999). Industrial Property and Pharmaceutical Industry: Opportunities and Challenges for Developing Countries, New York, Medical Publication Division